Elecsys^® total PSA and free PSA

Elecsys^® total PSA, a quantitative in vitro diagnostic test for determination of total (free + complexed) prostate specific antigen (tPSA) in human serum and plasma.

Prostate cancer is the second most common cancer in men and the leading death cause from cancer in men.¹ Early detection ensures timely management and treatment before prostate cancer can cause potentially fatal conditions.²

Screening approaches have reduced prostate cancer mortality in the USA and in Europe.^3,4,5 The most widely used screening tests for prostate cancer are digital rectal examination (DRE) in combination with serum total PSA.⁶

Guidelines recommend PSA screening in men at higher risk of developing prostate cancer, based on risk factors including age, family history and race.^7,8,9

Total PSA can also be used to do active surveillance, assess therapy response and for post-treatment follow up.¹⁰

The National Comprehensive Cancer Network (NCCN) and the European Association of Urology suggest testing every 2–4 years when PSA >1 ng/mL, with repeat testing up to 8 years later when PSA levels are <1 ng/mL.^8,9

Elecsys^® free PSA, a prostate specific antigen (free PSA) for the quantitative determination of free PSA in human serum and plasma.

Up to 80% of men with an elevated total PSA level of 4.0–10 ng/mL do not have prostate cancer.¹¹ In men with slightly elevated total PSA (3–10 ng/mL), free PSA helps to discriminate between benign conditions and prostate cancer, and reduces the number of unnecessary biopsies performed.^12,13,14

The free/total PSA ratio (% free PSA) detects 95% of prostate cancers and avoids unnecessary biopsy in 20% of men without prostate cancer (using a cut-off value of 25%).¹⁵

Elecsys^® total PSA and free PSA

• Elecsys^® total PSA and free PSA have highly reliable technical performance.¹⁶
  
• With a proven lot-to-lot consistency, Elecsys^® total PSA test is well suited for prostate cancer monitoring.¹⁷